Tags

Type your tag names separated by a space and hit enter

Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol.
BMJ Open. 2022 Feb 10; 12(2):e053838.BO

Abstract

INTRODUCTION

Influenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC. The Flutext-4U study aims to assess the impact of Flutext-4U to increase influenza immunisation in children and adolescents with SRMC.

METHODS AND ANALYSIS

This is a randomised controlled trial involving parents of children and adolescents (aged >6 months to <18 years) with SRMC receiving tertiary care at the Women's and Children's Hospital (WCH), Adelaide, South Australia, who are eligible for funded influenza immunisation with a hospital appointment between the start of the seasonal influenza vaccination season and 31 July 2021, their treating general practitioners (GPs), and WCH paediatric specialists.Parents (of children/adolescents with SRMC) are randomised (1:1 ratio) to standard care plus intervention (SMS reminder messages to parents; reminders (written correspondence) for their child's GP from the hospital's Paediatric Outpatients Department) or standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists) with randomisation stratified by age-group (<5, 5-14, >14 to <18 years).The primary outcome is influenza vaccination, as confirmed by the Australian Immunisation Register.The proportion vaccinated (primary outcome) will be compared between randomised groups using logistic regression, with adjustment made for age group at randomisation. The effect of treatment will be described using an OR with a 95% CI.

ETHICS AND DISSEMINATION

The protocol and all study materials have been reviewed and approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/20/WCHN/5). Results will be disseminated via peer-reviewed publication and at scientific meetings, professional and public forums.

TRIAL REGISTRATION NUMBER

Australian New Zealand Clinical Trials Registry (ACTRN12621000463875).

Authors+Show Affiliations

Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia jane.tuckerman@mcri.edu.au. Vaccine Uptake Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.Women's and Children's Health Network, North Adelaide, South Australia, Australia. Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia.Women's and Children's Health Network, North Adelaide, South Australia, Australia.Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Women's and Children's Health Network, North Adelaide, South Australia, Australia. Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Women's and Children's Health Network, North Adelaide, South Australia, Australia.Women's and Children's Health Network, North Adelaide, South Australia, Australia. Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Women's and Children's Health Network, North Adelaide, South Australia, Australia.Women's and Children's Health Network, North Adelaide, South Australia, Australia.Women's and Children's Health Network, North Adelaide, South Australia, Australia.Communicable Disease Control Branch, South Australian Department of Health and Wellbeing, Adelaide, South Australia, Australia.Vaccine Uptake Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University Western Australia, Perth, Western Australia, Australia. Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia. School of Medicine, University of Western Australia, Perth, Western Australia, Australia. Department of Microbiology, PathWest Laboratory Medicine WA, Perth, Western Australia, Australia.Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Women's and Children's Health Network, North Adelaide, South Australia, Australia. Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.

Pub Type(s)

Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35144952

Citation

Tuckerman, Jane, et al. "Using Provider-parent Strategies to Improve Influenza Vaccination in Children and Adolescents With Special Risk Medical Conditions: a Randomised Controlled Trial Protocol." BMJ Open, vol. 12, no. 2, 2022, pp. e053838.
Tuckerman J, Harper K, Sullivan TR, et al. Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol. BMJ Open. 2022;12(2):e053838.
Tuckerman, J., Harper, K., Sullivan, T. R., Fereday, J., Couper, J., Smith, N., Tai, A., Kelly, A., Couper, R., Friswell, M., Flood, L., Danchin, M., Blyth, C. C., & Marshall, H. (2022). Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol. BMJ Open, 12(2), e053838. https://doi.org/10.1136/bmjopen-2021-053838
Tuckerman J, et al. Using Provider-parent Strategies to Improve Influenza Vaccination in Children and Adolescents With Special Risk Medical Conditions: a Randomised Controlled Trial Protocol. BMJ Open. 2022 Feb 10;12(2):e053838. PubMed PMID: 35144952.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol. AU - Tuckerman,Jane, AU - Harper,Kelly, AU - Sullivan,Thomas R, AU - Fereday,Jennifer, AU - Couper,Jennifer, AU - Smith,Nicholas, AU - Tai,Andrew, AU - Kelly,Andrew, AU - Couper,Richard, AU - Friswell,Mark, AU - Flood,Louise, AU - Danchin,Margaret, AU - Blyth,Christopher C, AU - Marshall,Helen, Y1 - 2022/02/10/ PY - 2022/2/11/entrez PY - 2022/2/12/pubmed PY - 2022/4/12/medline KW - paediatric infectious disease & immunisation KW - preventive medicine KW - protocols & guidelines KW - public health SP - e053838 EP - e053838 JF - BMJ open JO - BMJ Open VL - 12 IS - 2 N2 - INTRODUCTION: Influenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC. The Flutext-4U study aims to assess the impact of Flutext-4U to increase influenza immunisation in children and adolescents with SRMC. METHODS AND ANALYSIS: This is a randomised controlled trial involving parents of children and adolescents (aged >6 months to <18 years) with SRMC receiving tertiary care at the Women's and Children's Hospital (WCH), Adelaide, South Australia, who are eligible for funded influenza immunisation with a hospital appointment between the start of the seasonal influenza vaccination season and 31 July 2021, their treating general practitioners (GPs), and WCH paediatric specialists.Parents (of children/adolescents with SRMC) are randomised (1:1 ratio) to standard care plus intervention (SMS reminder messages to parents; reminders (written correspondence) for their child's GP from the hospital's Paediatric Outpatients Department) or standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists) with randomisation stratified by age-group (<5, 5-14, >14 to <18 years).The primary outcome is influenza vaccination, as confirmed by the Australian Immunisation Register.The proportion vaccinated (primary outcome) will be compared between randomised groups using logistic regression, with adjustment made for age group at randomisation. The effect of treatment will be described using an OR with a 95% CI. ETHICS AND DISSEMINATION: The protocol and all study materials have been reviewed and approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/20/WCHN/5). Results will be disseminated via peer-reviewed publication and at scientific meetings, professional and public forums. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12621000463875). SN - 2044-6055 UR - https://www.unboundmedicine.com/medline/citation/35144952/Using_provider_parent_strategies_to_improve_influenza_vaccination_in_children_and_adolescents_with_special_risk_medical_conditions:_a_randomised_controlled_trial_protocol_ L2 - https://bmjopen.bmj.com/lookup/pmidlookup?view=long&amp;pmid=35144952 DB - PRIME DP - Unbound Medicine ER -